In last trading session, Humacyte Inc (NASDAQ:HUMA) saw 8.55 million shares changing hands with its beta currently measuring 1.69. Company’s recent per share price level of $1.87 trading at $0.14 or 8.09% at ring of the bell on the day assigns it a market valuation of $290.08M. That closing price of HUMA’s stock is at a discount of -433.16% from its 52-week high price of $9.97 and is indicating a premium of 38.5% from its 52-week low price of $1.15. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 5.06 million shares which gives us an average trading volume of 4.03 million if we extend that period to 3-months.
For Humacyte Inc (HUMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.18 in the current quarter.
Humacyte Inc (NASDAQ:HUMA) trade information
Upright in the green during last session for gaining 8.09%, in the last five days HUMA remained trading in the green while hitting it’s week-highest on Wednesday, 05/14/25 when the stock touched $1.87 price level, adding 8.56% to its value on the day. Humacyte Inc’s shares saw a change of -62.97% in year-to-date performance and have moved 53.28% in past 5-day. Humacyte Inc (NASDAQ:HUMA) showed a performance of 25.50% in past 30-days. Number of shares sold short was 25.15 million shares which calculate 5.65 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 68.83% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -167.38% in reaching the projected high whereas dropping to the targeted low would mean a loss of -167.38% for stock’s current value.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 935.86k for the same. And 7 analysts are in estimates of company making revenue of 2.34M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 42.43% during past 5 years.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Insiders are in possession of 20.16% of company’s total shares while institution are holding 29.51 percent of that, with stock having share float percentage of 36.97%. Investors also watch the number of corporate investors in a company very closely, which is 29.51% institutions for Humacyte Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at HUMA for having 7.14 million shares of worth $34.27 million. And as of 2024-06-30, it was holding 5.9912 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 4.73 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.9686 of outstanding shares, having a total worth of $22.7 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.59 shares of worth $4.85 million or 1.79% of the total outstanding shares. The later fund manager was in possession of 2.35 shares on Mar 31, 2025 , making its stake of worth around $4.4 million in the company or a holder of 1.62% of company’s stock.
